Corvus Pharmaceuticals (CRVS) Competitors $3.94 -0.05 (-1.13%) Closing price 02:54 PM EasternExtended Trading$3.96 +0.02 (+0.51%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. PAHC, WVE, ELVN, VERV, NTLA, COLL, AKBA, SYRE, MLYS, and AVDLShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Its Competitors Phibro Animal Health WAVE Life Sciences Enliven Therapeutics Verve Therapeutics Intellia Therapeutics Collegium Pharmaceutical Akebia Therapeutics Spyre Therapeutics Mineralys Therapeutics Avadel Pharmaceuticals Phibro Animal Health (NASDAQ:PAHC) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Does the media favor PAHC or CRVS? In the previous week, Phibro Animal Health had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Phibro Animal Health and 2 mentions for Corvus Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.33 beat Corvus Pharmaceuticals' score of -0.10 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of PAHC or CRVS? 99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 28.5% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, PAHC or CRVS? Phibro Animal Health has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Do analysts rate PAHC or CRVS? Phibro Animal Health currently has a consensus target price of $21.80, suggesting a potential downside of 22.12%. Corvus Pharmaceuticals has a consensus target price of $15.00, suggesting a potential upside of 281.19%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 2 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PAHC or CRVS more profitable? Phibro Animal Health has a net margin of 2.68% compared to Corvus Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health2.68% 30.51% 6.89% Corvus Pharmaceuticals N/A -24.04%-13.90% Which has preferable valuation & earnings, PAHC or CRVS? Phibro Animal Health has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.02B1.11$2.42M$0.7835.88Corvus PharmaceuticalsN/AN/A-$62.29M-$0.98-4.02 SummaryPhibro Animal Health beats Corvus Pharmaceuticals on 12 of the 15 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$271.31M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-4.0221.5627.4020.04Price / SalesN/A281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book7.727.518.085.67Net Income-$62.29M-$55.05M$3.16B$248.47M7 Day Performance-6.53%3.16%2.12%2.90%1 Month Performance-4.49%5.92%4.43%5.75%1 Year Performance121.07%5.82%35.62%21.36% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.503 of 5 stars$3.94-1.1%$15.00+281.2%+123.6%$271.31MN/A-4.0230Insider TradePAHCPhibro Animal Health3.662 of 5 stars$25.54-0.5%$21.80-14.6%+67.3%$1.04B$1.02B32.741,940News CoverageWVEWAVE Life Sciences4.161 of 5 stars$6.50-2.5%$20.50+215.4%+29.3%$1.04B$108.30M-7.74240ELVNEnliven Therapeutics2.5229 of 5 stars$20.06-3.0%$39.60+97.4%-4.9%$1.01BN/A-10.4550Analyst ForecastVERVVerve Therapeutics3.3086 of 5 stars$11.23-0.6%$14.57+29.8%+124.2%$1.01B$32.33M-5.32110NTLAIntellia Therapeutics4.6451 of 5 stars$9.38-1.9%$33.37+255.7%-51.6%$990.25M$57.88M-1.79600News CoverageCOLLCollegium Pharmaceutical4.0288 of 5 stars$29.57-1.2%$43.75+48.0%-4.8%$961.71M$631.45M24.24210AKBAAkebia Therapeutics4.36 of 5 stars$3.64-0.3%$6.75+85.4%+278.1%$958.62M$160.18M-17.33430Positive NewsInsider TradeSYRESpyre Therapeutics1.5676 of 5 stars$14.97-1.6%$53.40+256.7%-34.8%$917.39M$890K-3.9773MLYSMineralys Therapeutics2.1639 of 5 stars$13.53-1.3%$32.25+138.4%+18.3%$893.55MN/A-3.6328AVDLAvadel Pharmaceuticals2.4179 of 5 stars$8.85-3.8%$18.17+105.3%-36.6%$890M$169.12M-32.7870 Related Companies and Tools Related Companies Phibro Animal Health Alternatives WAVE Life Sciences Alternatives Enliven Therapeutics Alternatives Verve Therapeutics Alternatives Intellia Therapeutics Alternatives Collegium Pharmaceutical Alternatives Akebia Therapeutics Alternatives Spyre Therapeutics Alternatives Mineralys Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
